submit url • add directory • nursing jobs
Today's News:
All Hematology-Oncology Jobs
Make Your Mark at Texas Tech, No State Tax, New Medical School, 2nd-Safest Metro, #5185 :: Texas :: Timeline Recruiting
Join this expanding Department of Medicine and a group of academic and highly dedicated physicians during an exciting time of growth. There are opportunities to play a key role in developing the Hematology
West Texas Charm, Big City State Employed, No State Tax with Amazing Sign-On, #3364 :: Texas :: Timeline Recruiting
Enjoy the best of both worlds! In this position you will have the satisfaction of fostering the growth of tomorrows physicians, as well as working in a thriving practice. Be a part of a team that
Northern California, Pacific Coast City of 25K, #2672 :: California :: Timeline Recruiting
Enjoy arts, music festivals and theatre Superb Victorian Architecture Majestic Redwoods Beautiful Ocean Views Local Airport Local State University This charming coastal city is one of Northern
Hematological Oncology
Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors
Jing Zhang, Jonathan S Harrison, Milan Uskokovic, Michael Danilenko, George P Studzinski Wed, 28 Oct 2009 04:28:00 -0000
Induction of terminal differentiation is a conceptually attractive approach for the therapy of neoplastic diseases. Although vitamin D derivatives (deltanoids) can induce differentiation of AML cells in vitro, so far deltanoids have not been successfully brought to the clinic, due to the likelihood of life-threatening hypercalcemia. Here, we incubated freshly obtained blood cells from patients with AML with a plant antioxidant (PAOx), silibinin (SIL), alone or together with a deltanoid. Twenty patients with AML (all subtypes except M3) were available for this study, and in 14 (70%), SIL (60 µM) either induced differentiation ex vivo, or enhanced differentiation induced by deltanoids, or both. Interestingly, SIL acting alone induced differentiation only in cases in which chromosome aberrations could not be detected. In eleven samples sufficient material was available for a limited analysis of the underlying events. Quantitative RT-PCR showed that differentiation markers were upregulated at the mRNA level by both SIL and deltanoids, suggesting that intracellular signaling pathways upstream of transcription factors (TFs) were activated by these agents. Western analysis for proteins which function as TFs in deltanoid-induced monocytic differentiation, such as members of Jun and C/EBP families, surprisingly demonstrated that SIL upregulated all these TFs in the cases tested. This suggests that although the presence of SIL may not always be sufficient to induce differentiation, it can serve as a differentiation enabling factor for blasts obtained from a large proportion of patients with AML. Thus, SIL/deltanoid combinations warrant further consideration as preventive/therapeutic regimens in human leukaemia. Copyright © 2009 John Wiley & Sons, Ltd.
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
Cristiana Bellan, Lazzi Stefano, De Falco Giulia, Emily A Rogena, Leoncini Lorenzo Tue, 20 Oct 2009 22:14:00 -0000
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene. The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL). While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic and cytogenetics intermediate between DLBCL and BL, and cannot be classified with certainty in these categories. Distinguishing between BL and DLBCL is critical, as the two diseases require different management. This review summarizes the current practical approach, including the use of a large panel of antibodies, and cytogenetic and molecular diagnostic techniques, to distinguish between BL, DLBCL and the provisional category of 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma', now listed in the updated WHO classification. Copyright © 2009 John Wiley & Sons, Ltd.
Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program
Gregory A Abel, Kimberly A Bertrand, Craig C Earle, Francine Laden Wed, 28 Oct 2009 04:30:00 -0000
Vital statistics for the lymphoid malignancies obtained from the Surveillance, Epidemiology and End Results (SEER) Program have seldom been directly compared to data from alternative national databases. While SEER is recognized as the standard, some lymphoid malignancies - especially the chronic ones - may be underreported. We compared the incidence, all-cause and cause-specific mortality for Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) in SEER to that in the Nurses' Health Study (NHS), a national cohort study of 121 700 female registered nurses, matching for age and race. In over 2.5 million person-years, the incidence of HL was the same as in SEER (SIR = 1.01 [0.75, 1.26]), while the incidence of NHL, CLL and MM were slightly higher. All-cause mortality was lower for the lymphoid malignancies except for MM, which was the same; there were no differences in cause-specific mortality, except for MM (HR = 1.26 [1.07, 1.48]). Our analysis suggests that, at least among white women, SEER is a reliable data source with respect to lymphoid malignancies. Copyright © 2009 John Wiley & Sons, Ltd.
Annals of Hematology
Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma
Tue, 03 Nov 2009 21:11:50 -0000
Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0851-2Authors Yu-Chung Huang, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanZhi-Yi Xie, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanHsiou-Shan Tseng, Taipei Veterans General Hospital Department of Radiology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanChing-Feng Yang, Taipei Veterans General Hospital Department of Pathology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanLiang-Tsai Hsiao, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 Taiwan Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission
Thu, 29 Oct 2009 19:38:16 -0000
Abstract Patients with haematological disorders have previously been considered to have poor outcomes following admission to intensive care units. Although a number of haematology centres from outside the UK have now demonstrated improved outcomes, the continuing perception of poor outcomes in this patient group continues to adversely affect their chances of being admitted to some intensive care units (ICUs). Over the past 10 years, there have been many advances within the disciplines of both haematology and intensive care medicine. This study was done to assess outcomes and the impact of an early warning scoring system (EWS) and early involvement of ICU outreach teams. One hundred five haematology patients (haematopoietic stem cell transplant (HSCT) or non-HSCT) had 114 admissions to ICU between April 2006 and August 2008 which coincided with hospital-wide implementation of EWS. The survival to ICU discharge was 56 (53%). Thirty-three (33%) patients were alive at 6 months giving a 1-year survival of 31%. Of the 39 HSCT patients, nine were post-autologous and 30 post-allogeneic transplant. The survival to ICU discharge was 22 (56%) with 14 (36%) patients alive at 6 months. One year survival was 36%. Prior to the introduction of EWS and critical care outreach team (2004), survival to ICU discharge was 44% which has increased to 53% (2006–2008). This is despite an increase in mechanical ventilation in 2006–2008 (50%) as compared to 2004 (32%).The improvement in ICU survivorship was even more prominent in HSCT patients (37% in 2004 versus 56% in 2006–2008). There was a trend towards decreasing Acute Physiology and Chronic Health Evaluation scores with time, suggesting appropriate patients being identified earlier and having timely escalation of their treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0853-0Authors Syed W. I. Bokhari, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKTalha Munir, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKShabeeha Memon, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKJenny L. Byrne, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKNigel H. Russell, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKMartin Beed, Nottingham University Hospitals—City Campus Critical Care Department Nottingham UK Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
Fri, 23 Oct 2009 18:52:52 -0000
Abstract Lenalidomide consistently induces transfusion independence and complete cytogenetic response in patients with myelodysplastic syndromes with 5q deletion. Only limited information on long-term outcome is currently available. We performed a long-term follow-up analysis of 42 patients with low or intermediate risk myelodysplastic syndromes and 5q deletion treated with lenalidomide. At a median follow-up of 40 months, 58% of the patients achieved an erythroid response and 48% a cytogenetic response. Thirty-six percent of patients progressed into acute myeloid leukaemia. Most of them (87%) acquired chromosome aberrations in addition to the 5q deletion, i.e. underwent clonal evolution during leukaemogenesis. There were no clinical, cytological or cytogenetic markers at study entry that allowed prediction of increased risk of leukaemic transformation. However, erythroid and cytogenetic responders had a significantly decreased risk of progression to acute myeloid leukaemia (p = 0.001 and p = 0.009, respectively) compared to non-responders. Three and 5 years after study entry, the cumulative incidence of acute myeloid leukaemia for patients with a cytogenetic response was 10% and 21%, respectively, and for patients without cytogenetic response, it was 46% and 60%. Patients with del(5q) myelodysplastic syndromes without erythroid or cytogenetic remission after treatment with lenalidomide have a high risk for clonal evolution and acute myeloid leukaemia progression. In refractory, or relapsing, patients, genetic instability and clonal evolution seem to be the driving forces of leukaemic transformation. Regular follow-up investigations of del(5q) myelodysplastic syndrome patients treated with lenalidomide may help to identify patients requiring alternative treatment strategies. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0846-zAuthors Gudrun Göhring, Hannover Medical School Institute of Cell and Molecular Pathology Carl-Neuberg-Str. 1 30625 Hannover GermanyAristoteles Giagounidis, St. Johannes Hospital Department of Haematology, Oncology and Clinical Immunology Duisburg GermanyGuntram Büsche, Hannover Medical School Institute of Pathology Hannover GermanyHans Heinrich Kreipe, Hannover Medical School Institute of Pathology Hannover GermanyMartin Zimmermann, Hannover Medical School Department of Paediatric Haematology/Oncology Hannover GermanyEva Hellström-Lindberg, Karolinska University Hospital Division of Haematology and Centre of Experimental Haematology, Department of Medicine, Karolinska Institutet Stockholm SwedenCarlo Aul, St. Johannes Hospital Department of Haematology, Oncology and Clinical Immunology Duisburg GermanyBrigitte Schlegelberger, Hannover Medical School Institute of Cell and Molecular Pathology Carl-Neuberg-Str. 1 30625 Hannover Germany Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
American Journal of Hematology
On being metachromatic: Mystique and misunderstanding in mastocytosis
Jason Gotlib Fri, 23 Oct 2009 14:51:00 -0000
No abstract.
Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
Martha Q. Lacy, Sumithra Mandrekar, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, David Dingli, Mark Litzow, Peter Wettstein, Douglas Padley, Brian Kabat, Dennis Gastineau, S. Vincent Rajkumar, Morie A. Gertz Fri, 09 Oct 2009 14:05:00 -0000
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (MylovengeTM), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty-seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124 consecutive patients transplanted during the same period, but not enrolled on the trial. The median (range) follow-up for patients still alive from the vaccine trial is 6.5 (2.9-8 years), and 7.1 (6-8 years) in the control group. The median age was 57.4 range (36.1-71.3) in the DB group and 56.4 (range, 30-69) in the trial group. Known prognostic factors including PCLI, B2M, and CRP were comparable between the groups. The median overall survival for the trial patients was 5.3 years (95% CI: 4.0 years - N/A) compared to 3.4 years (95% CI: 2.7-4.6 years) for the DB group (P = 0.02). The median time to progression and progression-free survival for the trial group was similar to the DB group. Although not a controlled trial, the vaccines given after ASCT appear to be associated with improved overall survival compared to historical controls. This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma. Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.
Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma
Hee Nam Kim, Nan Young Kim, Li Yu, Yeo-Kyeoung Kim, Il-Kwon Lee, Deok-Hwan Yang, Je-Jung Lee, Min-Ho Shin, Kyeong-Soo Park, Jin-Su Choi, Hyeoung-Joon Kim Thu, 08 Oct 2009 11:45:00 -0000
Drug metabolizing genes are involved in the detoxification of chemical carcinogens. Polymorphisms in drug-metabolizing genes affect the risk of some forms of cancer. We analyzed six polymorphisms to evaluate their association with risk for non-Hodgkin lymphoma (NHL), and to examine whether smoking modifies these associations in population-based study in Korea (713 cases and 1,700 controls). The GSTP1 rs1695 AG and the combined AG/GG genotypes were associated with decreased risk of NHL (odds ratio (OR)AG = 0.67, 95% confidence interval (CI) = 0.55-0.82; ORAG/GG = 0.66, 95% CI = 0.54-0.80) and DLBCL (ORAG = 0.63, 95% CI = 0.49-0.82; ORAG/GG = 0.64, 95% CI = 0.50-0.82). For T-cell lymphoma, only the combined AG/GG genotype was associated with decreased risk (ORAG/GG = 0.65, 95% CI = 0.44-0.96). The CYP1A1 rs1048943 AG genotype and the combined AG/GG genotypes were associated with increased risk of NHL (ORAG = 1.28, 95% CI = 1.07-1.54; ORAG/GG = 1.26, 95% CI = 1.06-1.51) and DLBCL (ORAG = 1.32, 95% CI = 1.04-1.66; ORAG/GG = 1.30, 95% CI = 1.03-1.63), but not T-cell lymphoma. Smoking does not modify the association between these polymorphisms and NHL risk. Our data provide evidence that the GSTP1 rs1695 and the CYP1A1 rs1048943 genotypes affect the risk of NHL in Korea. Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.
Pediatric Hematology and Oncology: Articles recently published in
CLINICAL PROFILE AND HOME MANAGEMENT OF SICKLE CELL-RELATED PAIN: The Enugu (Nigeria) Experience
Ocheni, SundayEmodi, Ifeoma J.Ikefuna, Anthony N. Wed, 01 Jul 2009 00:00:00 -0000
THE BENEFIT OF ATG IN IMMUNOSUPPRESSIVE THERAPY OF CHILDREN WITH MODERATE APLASTIC ANEMIA
Xie, XiaotianKuang, HanqinLin, JieliangQiao, XiaohongShao, YuexiaShi, WeiJiang, ShayiWang, Yaoping Wed, 01 Jul 2009 00:00:00 -0000
RHABDOMYOSARCOMA OF THE EXTREMITIES: A Focus on Tumors Arising in the Hand and Foot
Ferrari, AndreaMorosi, CarloFiore, MarcoFavini, FrancescaMeazza, CristinaCasanova, Michela Wed, 01 Jul 2009 00:00:00 -0000
Subscribe to Hematology RSS feed 
Make Your Mark at Texas Tech, No State Tax, New Medical School, 2nd-Safest Metro, #5185 :: Texas :: Timeline Recruiting
Join this expanding Department of Medicine and a group of academic and highly dedicated physicians during an exciting time of growth. There are opportunities to play a key role in developing the Hematology
West Texas Charm, Big City State Employed, No State Tax with Amazing Sign-On, #3364 :: Texas :: Timeline Recruiting
Enjoy the best of both worlds! In this position you will have the satisfaction of fostering the growth of tomorrows physicians, as well as working in a thriving practice. Be a part of a team that
Northern California, Pacific Coast City of 25K, #2672 :: California :: Timeline Recruiting
Enjoy arts, music festivals and theatre Superb Victorian Architecture Majestic Redwoods Beautiful Ocean Views Local Airport Local State University This charming coastal city is one of Northern
Hematological Oncology
Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors
Jing Zhang, Jonathan S Harrison, Milan Uskokovic, Michael Danilenko, George P Studzinski Wed, 28 Oct 2009 04:28:00 -0000
Induction of terminal differentiation is a conceptually attractive approach for the therapy of neoplastic diseases. Although vitamin D derivatives (deltanoids) can induce differentiation of AML cells in vitro, so far deltanoids have not been successfully brought to the clinic, due to the likelihood of life-threatening hypercalcemia. Here, we incubated freshly obtained blood cells from patients with AML with a plant antioxidant (PAOx), silibinin (SIL), alone or together with a deltanoid. Twenty patients with AML (all subtypes except M3) were available for this study, and in 14 (70%), SIL (60 µM) either induced differentiation ex vivo, or enhanced differentiation induced by deltanoids, or both. Interestingly, SIL acting alone induced differentiation only in cases in which chromosome aberrations could not be detected. In eleven samples sufficient material was available for a limited analysis of the underlying events. Quantitative RT-PCR showed that differentiation markers were upregulated at the mRNA level by both SIL and deltanoids, suggesting that intracellular signaling pathways upstream of transcription factors (TFs) were activated by these agents. Western analysis for proteins which function as TFs in deltanoid-induced monocytic differentiation, such as members of Jun and C/EBP families, surprisingly demonstrated that SIL upregulated all these TFs in the cases tested. This suggests that although the presence of SIL may not always be sufficient to induce differentiation, it can serve as a differentiation enabling factor for blasts obtained from a large proportion of patients with AML. Thus, SIL/deltanoid combinations warrant further consideration as preventive/therapeutic regimens in human leukaemia. Copyright © 2009 John Wiley & Sons, Ltd.
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach
Cristiana Bellan, Lazzi Stefano, De Falco Giulia, Emily A Rogena, Leoncini Lorenzo Tue, 20 Oct 2009 22:14:00 -0000
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene. The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL). While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic and cytogenetics intermediate between DLBCL and BL, and cannot be classified with certainty in these categories. Distinguishing between BL and DLBCL is critical, as the two diseases require different management. This review summarizes the current practical approach, including the use of a large panel of antibodies, and cytogenetic and molecular diagnostic techniques, to distinguish between BL, DLBCL and the provisional category of 'B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma', now listed in the updated WHO classification. Copyright © 2009 John Wiley & Sons, Ltd.
Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program
Gregory A Abel, Kimberly A Bertrand, Craig C Earle, Francine Laden Wed, 28 Oct 2009 04:30:00 -0000
Vital statistics for the lymphoid malignancies obtained from the Surveillance, Epidemiology and End Results (SEER) Program have seldom been directly compared to data from alternative national databases. While SEER is recognized as the standard, some lymphoid malignancies - especially the chronic ones - may be underreported. We compared the incidence, all-cause and cause-specific mortality for Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) in SEER to that in the Nurses' Health Study (NHS), a national cohort study of 121 700 female registered nurses, matching for age and race. In over 2.5 million person-years, the incidence of HL was the same as in SEER (SIR = 1.01 [0.75, 1.26]), while the incidence of NHL, CLL and MM were slightly higher. All-cause mortality was lower for the lymphoid malignancies except for MM, which was the same; there were no differences in cause-specific mortality, except for MM (HR = 1.26 [1.07, 1.48]). Our analysis suggests that, at least among white women, SEER is a reliable data source with respect to lymphoid malignancies. Copyright © 2009 John Wiley & Sons, Ltd.
Annals of Hematology
Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma
Tue, 03 Nov 2009 21:11:50 -0000
Splenic artery pseudoaneurysm with rupture by transformed splenic marginal zone B cell lymphoma Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0851-2Authors Yu-Chung Huang, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanZhi-Yi Xie, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanHsiou-Shan Tseng, Taipei Veterans General Hospital Department of Radiology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanChing-Feng Yang, Taipei Veterans General Hospital Department of Pathology No. 201, Sec. 2, Shipai Rd Taipei 112 TaiwanLiang-Tsai Hsiao, Taipei Veterans General Hospital Division of Hematology & Oncology, Department of Medicine No. 201, Sec. 2, Shipai Rd Taipei 112 Taiwan Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Impact of critical care reconfiguration and track-and-trigger outreach team intervention on outcomes of haematology patients requiring intensive care admission
Thu, 29 Oct 2009 19:38:16 -0000
Abstract Patients with haematological disorders have previously been considered to have poor outcomes following admission to intensive care units. Although a number of haematology centres from outside the UK have now demonstrated improved outcomes, the continuing perception of poor outcomes in this patient group continues to adversely affect their chances of being admitted to some intensive care units (ICUs). Over the past 10 years, there have been many advances within the disciplines of both haematology and intensive care medicine. This study was done to assess outcomes and the impact of an early warning scoring system (EWS) and early involvement of ICU outreach teams. One hundred five haematology patients (haematopoietic stem cell transplant (HSCT) or non-HSCT) had 114 admissions to ICU between April 2006 and August 2008 which coincided with hospital-wide implementation of EWS. The survival to ICU discharge was 56 (53%). Thirty-three (33%) patients were alive at 6 months giving a 1-year survival of 31%. Of the 39 HSCT patients, nine were post-autologous and 30 post-allogeneic transplant. The survival to ICU discharge was 22 (56%) with 14 (36%) patients alive at 6 months. One year survival was 36%. Prior to the introduction of EWS and critical care outreach team (2004), survival to ICU discharge was 44% which has increased to 53% (2006–2008). This is despite an increase in mechanical ventilation in 2006–2008 (50%) as compared to 2004 (32%).The improvement in ICU survivorship was even more prominent in HSCT patients (37% in 2004 versus 56% in 2006–2008). There was a trend towards decreasing Acute Physiology and Chronic Health Evaluation scores with time, suggesting appropriate patients being identified earlier and having timely escalation of their treatment. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0853-0Authors Syed W. I. Bokhari, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKTalha Munir, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKShabeeha Memon, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKJenny L. Byrne, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKNigel H. Russell, Nottingham University Hospitals—City Campus Department of Clinical Haematology Nottingham UKMartin Beed, Nottingham University Hospitals—City Campus Critical Care Department Nottingham UK Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression
Fri, 23 Oct 2009 18:52:52 -0000
Abstract Lenalidomide consistently induces transfusion independence and complete cytogenetic response in patients with myelodysplastic syndromes with 5q deletion. Only limited information on long-term outcome is currently available. We performed a long-term follow-up analysis of 42 patients with low or intermediate risk myelodysplastic syndromes and 5q deletion treated with lenalidomide. At a median follow-up of 40 months, 58% of the patients achieved an erythroid response and 48% a cytogenetic response. Thirty-six percent of patients progressed into acute myeloid leukaemia. Most of them (87%) acquired chromosome aberrations in addition to the 5q deletion, i.e. underwent clonal evolution during leukaemogenesis. There were no clinical, cytological or cytogenetic markers at study entry that allowed prediction of increased risk of leukaemic transformation. However, erythroid and cytogenetic responders had a significantly decreased risk of progression to acute myeloid leukaemia (p = 0.001 and p = 0.009, respectively) compared to non-responders. Three and 5 years after study entry, the cumulative incidence of acute myeloid leukaemia for patients with a cytogenetic response was 10% and 21%, respectively, and for patients without cytogenetic response, it was 46% and 60%. Patients with del(5q) myelodysplastic syndromes without erythroid or cytogenetic remission after treatment with lenalidomide have a high risk for clonal evolution and acute myeloid leukaemia progression. In refractory, or relapsing, patients, genetic instability and clonal evolution seem to be the driving forces of leukaemic transformation. Regular follow-up investigations of del(5q) myelodysplastic syndrome patients treated with lenalidomide may help to identify patients requiring alternative treatment strategies. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00277-009-0846-zAuthors Gudrun Göhring, Hannover Medical School Institute of Cell and Molecular Pathology Carl-Neuberg-Str. 1 30625 Hannover GermanyAristoteles Giagounidis, St. Johannes Hospital Department of Haematology, Oncology and Clinical Immunology Duisburg GermanyGuntram Büsche, Hannover Medical School Institute of Pathology Hannover GermanyHans Heinrich Kreipe, Hannover Medical School Institute of Pathology Hannover GermanyMartin Zimmermann, Hannover Medical School Department of Paediatric Haematology/Oncology Hannover GermanyEva Hellström-Lindberg, Karolinska University Hospital Division of Haematology and Centre of Experimental Haematology, Department of Medicine, Karolinska Institutet Stockholm SwedenCarlo Aul, St. Johannes Hospital Department of Haematology, Oncology and Clinical Immunology Duisburg GermanyBrigitte Schlegelberger, Hannover Medical School Institute of Cell and Molecular Pathology Carl-Neuberg-Str. 1 30625 Hannover Germany Journal Annals of HematologyOnline ISSN 1432-0584Print ISSN 0939-5555
American Journal of Hematology
On being metachromatic: Mystique and misunderstanding in mastocytosis
Jason Gotlib Fri, 23 Oct 2009 14:51:00 -0000
No abstract.
Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
Martha Q. Lacy, Sumithra Mandrekar, Angela Dispenzieri, Suzanne Hayman, Shaji Kumar, Francis Buadi, David Dingli, Mark Litzow, Peter Wettstein, Douglas Padley, Brian Kabat, Dennis Gastineau, S. Vincent Rajkumar, Morie A. Gertz Fri, 09 Oct 2009 14:05:00 -0000
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (MylovengeTM), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty-seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124 consecutive patients transplanted during the same period, but not enrolled on the trial. The median (range) follow-up for patients still alive from the vaccine trial is 6.5 (2.9-8 years), and 7.1 (6-8 years) in the control group. The median age was 57.4 range (36.1-71.3) in the DB group and 56.4 (range, 30-69) in the trial group. Known prognostic factors including PCLI, B2M, and CRP were comparable between the groups. The median overall survival for the trial patients was 5.3 years (95% CI: 4.0 years - N/A) compared to 3.4 years (95% CI: 2.7-4.6 years) for the DB group (P = 0.02). The median time to progression and progression-free survival for the trial group was similar to the DB group. Although not a controlled trial, the vaccines given after ASCT appear to be associated with improved overall survival compared to historical controls. This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma. Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.
Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma
Hee Nam Kim, Nan Young Kim, Li Yu, Yeo-Kyeoung Kim, Il-Kwon Lee, Deok-Hwan Yang, Je-Jung Lee, Min-Ho Shin, Kyeong-Soo Park, Jin-Su Choi, Hyeoung-Joon Kim Thu, 08 Oct 2009 11:45:00 -0000
Drug metabolizing genes are involved in the detoxification of chemical carcinogens. Polymorphisms in drug-metabolizing genes affect the risk of some forms of cancer. We analyzed six polymorphisms to evaluate their association with risk for non-Hodgkin lymphoma (NHL), and to examine whether smoking modifies these associations in population-based study in Korea (713 cases and 1,700 controls). The GSTP1 rs1695 AG and the combined AG/GG genotypes were associated with decreased risk of NHL (odds ratio (OR)AG = 0.67, 95% confidence interval (CI) = 0.55-0.82; ORAG/GG = 0.66, 95% CI = 0.54-0.80) and DLBCL (ORAG = 0.63, 95% CI = 0.49-0.82; ORAG/GG = 0.64, 95% CI = 0.50-0.82). For T-cell lymphoma, only the combined AG/GG genotype was associated with decreased risk (ORAG/GG = 0.65, 95% CI = 0.44-0.96). The CYP1A1 rs1048943 AG genotype and the combined AG/GG genotypes were associated with increased risk of NHL (ORAG = 1.28, 95% CI = 1.07-1.54; ORAG/GG = 1.26, 95% CI = 1.06-1.51) and DLBCL (ORAG = 1.32, 95% CI = 1.04-1.66; ORAG/GG = 1.30, 95% CI = 1.03-1.63), but not T-cell lymphoma. Smoking does not modify the association between these polymorphisms and NHL risk. Our data provide evidence that the GSTP1 rs1695 and the CYP1A1 rs1048943 genotypes affect the risk of NHL in Korea. Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.
Pediatric Hematology and Oncology: Articles recently published in
CLINICAL PROFILE AND HOME MANAGEMENT OF SICKLE CELL-RELATED PAIN: The Enugu (Nigeria) Experience
Ocheni, SundayEmodi, Ifeoma J.Ikefuna, Anthony N. Wed, 01 Jul 2009 00:00:00 -0000
THE BENEFIT OF ATG IN IMMUNOSUPPRESSIVE THERAPY OF CHILDREN WITH MODERATE APLASTIC ANEMIA
Xie, XiaotianKuang, HanqinLin, JieliangQiao, XiaohongShao, YuexiaShi, WeiJiang, ShayiWang, Yaoping Wed, 01 Jul 2009 00:00:00 -0000
RHABDOMYOSARCOMA OF THE EXTREMITIES: A Focus on Tumors Arising in the Hand and Foot
Ferrari, AndreaMorosi, CarloFiore, MarcoFavini, FrancescaMeazza, CristinaCasanova, Michela Wed, 01 Jul 2009 00:00:00 -0000
Sites:
BloodLine: BloodLine is dedicated to furthering and enhancing the fields of hematology and oncology through the presentation of knowledge in the following manners: the publication of original clinical and laboratory research; the creation of comprehensive reference works that are continuously useful to...Atlas of hematology: The Atlas of Haematology contains about 700 illustrations of blood and bone marrow cells
Atlas of Hematology: CDROM Atlas of hematology with 1500 color images, by Prof. John Meletis. Range of examples available online.
Atlas of Hematology: Contains images of blood cells with descriptions.
Aurea R. Tomeski, M.D.: Dr. Tomeski - Internal Medicine - Hematology - Oncology
BloodMed: BloodMed.com - The global source for hematology education, practice and research
European Federation for Immunogenetics: Website for the European Federation of Immunogenetics.
Factor Replacement by Continuous Infusion: Guide for health professionals who provide continuous infusion clotting factor replacement therapy to individuals with bleeding disorders. Describes theory behind how to prescribe, administer, and monitor replacement therapy.
Family Practice Notebook: Hematology and Oncology: Find chapters about Anemia, Cancer, Coagulopathy, Examination, Hemoglobin, Hemolysis, Histiocytosis, Leukemia, Lymph, Marrow, Platelet, Procedure, Sarcoma, Symptom Evaluation and Vascular. Related chapters from other specialties include Cardiovascular, Dermatology, Endocrinology, Otolaryngology,...
General Practice Notebook - Haematology: Coverage of this medical speciality.
Haem.net: Haem.net - The Web Journal of Laboratory Haematology to serve the educational needs of anyone with an interest in Laboratory Haematology in the U.K. and overseas
Haematological Malignancy Diagnostic Service: The diagnosis of leukaemia, lymphoma, myeloma and related blood disorders by cellular and molecular investigation. Contents include the current classification of the myeloproliferative and lymphoproliferative disorders, morphology and cytochemistry, and diagnostic procedures including antibody ba...
Haematology: Haematology & Pathology Education Website for medical laboratory officer`s student or a clinical haematologist in training. Contains an Interactice questions and answers style haematology atlas set of slides. its an online hematology book. particularly useful for hematologists and pathologist...
Hematology: Wikipedia article describing branch of medicine, related diseases, tests, and treatments.
Hematology and Oncology Associates Of Virginia: Virginia Cancer Institute is dedicated to the highest quality medical care for the treatment of diseases of the blood (hematology) to the long-term management of cancer for our patients .
Hematology jobs: Hematology jobs at Physician Employment with automatic email updates.
Hematology, by Ellen C. Ebert, MD: Grant-funded research report which requires the Adobe Acrobat Reader to view.
Hematopathology Correlative Pathology Course: From the UAB Department of Pathology, Birmingham, Alabama.
Machaon Diagnostics: Clinical reference laboratory developing products for diagnosis and monitoring of hemostatic and thrombotic conditions.
Ortho-WIRE: Educational resource for transfusion medicine applications in immuno-hematology, blood group serology, and hemolytic disease of the newborn.
The Vanderbilt Hemostasis-Thrombosis Clinic: The Vanderbilt Hemostasis-Thrombosis Clinic provides comprehensive care for inherited disorders of bleeding or coagulation. Committed to patient care, education, and clinical research, we have over 75 years of experience caring for people with hemophilia, thrombophilia, and other blood disorders.
This directory is based on the Open Directory and may have been modified
